These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 9246959)

  • 21. The role of coagulation and fibrinolysis in preeclampsia.
    Bonnar J; Redman CW; Denson KW
    Perspect Nephrol Hypertens; 1976; 5():85-93. PubMed ID: 1005056
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alterations in fibrin formation and fibrinolysis in early onset-preeclampsia: Association with disease severity.
    Haire G; Egan K; Parmar K; McKinnon T; Monteith C; O'Connor H; Kevane B; Maguire P; Szklanna PB; Galligan M; Donnelly JC; Allen S; McCallion N; Hunt B; Áinle FN
    Eur J Obstet Gynecol Reprod Biol; 2019 Oct; 241():19-23. PubMed ID: 31415952
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Studies on blood coagulation-fibrinolysis system regarding kallikrein-kinin system in the utero-placental circulation during normal pregnancy, labor and puerperium.
    Mutoh S; Kobayashi M; Hirata J; Itoh N; Maki M; Komatsu Y; Yoshida A; Sasa H; Kuroda K; Kikuchi Y
    Agents Actions Suppl; 1992; 38 ( Pt 2)():320-9. PubMed ID: 1462839
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Levels of plasminogen activators and their inhibitors in maternal and umbilical cord plasma in severe preeclampsia.
    Roes EM; Sweep CG; Thomas CM; Zusterzeel PL; Geurts-Moespot A; Peters WH; Steegers EA
    Am J Obstet Gynecol; 2002 Oct; 187(4):1019-25. PubMed ID: 12388999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Coagulation and fibrinolysis related cytokine imbalance in preeclampsia: the role of placental trophoblasts.
    Teng YC; Lin QD; Lin JH; Ding CW; Zuo Y
    J Perinat Med; 2009; 37(4):343-8. PubMed ID: 19290852
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endoglin in pregnancy complicated by fetal intrauterine growth restriction in normotensive and preeclamptic pregnant women: a comparison between preeclamptic patients with appropriate-for-gestational-age weight infants and healthy pregnant women.
    Laskowska M; Laskowska K; Oleszczuk J
    J Matern Fetal Neonatal Med; 2012 Jun; 25(6):806-11. PubMed ID: 21793708
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Degree of hypercoagulability and hyperfibrinolysis is related to organ failure and prognosis after burn trauma.
    García-Avello A; Lorente JA; Cesar-Perez J; García-Frade LJ; Alvarado R; Arévalo JM; Navarro JL; Esteban A
    Thromb Res; 1998 Jan; 89(2):59-64. PubMed ID: 9630308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The relation of maternal serum eNOS, NOSTRIN and ADMA levels with aetiopathogenesis of preeclampsia and/or intrauterine fetal growth restriction.
    Laskowska M; Laskowska K; Oleszczuk J
    J Matern Fetal Neonatal Med; 2015 Jan; 28(1):26-32. PubMed ID: 24588201
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activation of both coagulation and fibrinolysis in childhood hemolytic uremic syndrome.
    Van Geet C; Proesmans W; Arnout J; Vermylen J; Declerck PJ
    Kidney Int; 1998 Oct; 54(4):1324-30. PubMed ID: 9767551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evidence of increased oxidative stress and a change in the plasminogen activator inhibitor (PAI)-1 to PAI-2 ratio in early-onset but not late-onset preeclampsia.
    Wikström AK; Nash P; Eriksson UJ; Olovsson MH
    Am J Obstet Gynecol; 2009 Dec; 201(6):597.e1-8. PubMed ID: 19683696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alternations of maternal and cord plasma hemostasis in preeclampsia before and after delivery.
    Xiong Y; Zhou SF; Zhou R; Yang D; Xu ZF; Lou YT; Guo QS; Hu R; Peng T; Ma D; Li XT
    Hypertens Pregnancy; 2011; 30(3):347-58. PubMed ID: 21174589
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Abnormal expression of type 1 plasminogen activator inhibitor and tissue factor in severe preeclampsia.
    Estellés A; Gilabert J; Grancha S; Yamamoto K; Thinnes T; España F; Aznar J; Loskutoff DJ
    Thromb Haemost; 1998 Mar; 79(3):500-8. PubMed ID: 9580327
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increase in the D-dimer levels during treatment in patients with acute myelogenous leukemia.
    Velasco F; Torres A; Rojas R; Alvarez MA; Gomez P; Castillo D
    Haemostasis; 1992; 22(3):117-23. PubMed ID: 1427455
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activation of the fibrinolytic system and utilization of the coagulation inhibitors in sepsis: comparison with severe sepsis and septic shock.
    Mavrommatis AC; Theodoridis T; Economou M; Kotanidou A; El Ali M; Christopoulou-Kokkinou V; Zakynthinos SG
    Intensive Care Med; 2001 Dec; 27(12):1853-9. PubMed ID: 11797019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: association with increased plasminogen activator inhibitor-1.
    Aso Y; Matsumoto S; Fujiwara Y; Tayama K; Inukai T; Takemura Y
    Metabolism; 2002 Apr; 51(4):471-6. PubMed ID: 11912556
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Elevation of plasma free PAI-1 levels as an integrated endothelial response to severe burns.
    Aoki K; Aikawa N; Sekine K; Yamazaki M; Mimura T; Urano T; Takada A
    Burns; 2001 Sep; 27(6):569-75. PubMed ID: 11525850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of plasminogen activators and plasminogen activator inhibitors in plasma and amniotic fluid in pregnancies complicated with intrauterine fetal growth retardation.
    Gilabert J; Estellés A; Ayuso MJ; España F; Chirivella M; Grancha S; Micó JM; Aznar J
    Gynecol Obstet Invest; 1994; 38(3):157-62. PubMed ID: 8001867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An enhanced fibrinolysis prevents the development of multiple organ failure in disseminated intravascular coagulation in spite of much activation of blood coagulation.
    Asakura H; Ontachi Y; Mizutani T; Kato M; Saito M; Kumabashiri I; Morishita E; Yamazaki M; Aoshima K; Nakao S
    Crit Care Med; 2001 Jun; 29(6):1164-8. PubMed ID: 11395595
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation.
    Watanabe R; Wada H; Watanabe Y; Sakakura M; Nakasaki T; Mori Y; Nishikawa M; Gabazza EC; Nobori T; Shiku H
    Thromb Res; 2001 Oct; 104(1):1-6. PubMed ID: 11583733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tissue-type plasminogen activator, type 1 plasminogen activator inhibitor and their complex in plasma with disseminated intravascular coagulation.
    Fukao H; Ueshima S; Okada K; Yamamoto K; Matsuo T; Matsuo O
    Thromb Res; 1992 Oct; 68(1):57-65. PubMed ID: 1280377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.